BI 1358894

BI 1358894 is an investigational antidepressant that works as a transient receptor potential cation channel inhibitor. It is developed by Boehringer Ingelheim.^[1]^[2]^[3]^[4]

References

^ Fuertig, René; Goettel, Markus; Herich, Lena; Hoefler, Josef; Wiebe, Sabrina T.; Sharma, Vikas (29 November 2023). "Effects of Single and Multiple Ascending Doses of BI 1358894 in Healthy Male Volunteers on Safety, Tolerability and Pharmacokinetics: Two Phase I Partially Randomised Studies". CNS Drugs. 37 (12): 1081–1097. doi:10.1007/s40263-023-01041-4. PMC 10703969. PMID 38019355.
^ Grimm, Simone; Keicher, Christian; Paret, Christian; Niedtfeld, Inga; Beckmann, Christian; Mennes, Maarten; Just, Stefan; Sharma, Vikas; Fuertig, René; Herich, Lena; Mack, Salome; Thamer, Claus; Schultheis, Christian; Weigand, Anne; Schmahl, Christian; Wunder, Andreas (December 2022). "The effects of transient receptor potential cation channel inhibition by BI 1358894 on cortico-limbic brain reactivity to negative emotional stimuli in major depressive disorder". European Neuropsychopharmacology. 65: 44–51. doi:10.1016/j.euroneuro.2022.10.009. hdl:2066/286079. PMID 36343427.
^ Goettel, Markus; Fuertig, Rene; Mack, Salome Rebecca; Just, Stefan; Sharma, Vikas; Wunder, Andreas; den Boer, Johan (29 November 2023). "Effect of BI 1358894 on Cholecystokinin-Tetrapeptide (CCK-4)-Induced Anxiety, Panic Symptoms, and Stress Biomarkers: A Phase I Randomized Trial in Healthy Males". CNS Drugs. 37 (12): 1099–1109. doi:10.1007/s40263-023-01042-3. PMC 10703963. PMID 38019356.
^ Goettel, Markus; Höfler, Josef; Fuertig, Rene; Sharma, Vikas; Göttel, Markus (May 2020). "First-In-Human Study of Oral BI 1358894 in Healthy Male Volunteers: A Phase I Study to Investigate Safety and Tolerability". Biological Psychiatry. 87 (9): S289–S290. doi:10.1016/j.biopsych.2020.02.747. S2CID 218537025.

[1] Fuertig, René; Goettel, Markus; Herich, Lena; Hoefler, Josef; Wiebe, Sabrina T.; Sharma, Vikas (29 November 2023). "Effects of Single and Multiple Ascending Doses of BI 1358894 in Healthy Male Volunteers on Safety, Tolerability and Pharmacokinetics: Two Phase I Partially Randomised Studies". CNS Drugs. 37 (12): 1081–1097. doi:10.1007/s40263-023-01041-4. PMC 10703969. PMID 38019355.

[2] Grimm, Simone; Keicher, Christian; Paret, Christian; Niedtfeld, Inga; Beckmann, Christian; Mennes, Maarten; Just, Stefan; Sharma, Vikas; Fuertig, René; Herich, Lena; Mack, Salome; Thamer, Claus; Schultheis, Christian; Weigand, Anne; Schmahl, Christian; Wunder, Andreas (December 2022). "The effects of transient receptor potential cation channel inhibition by BI 1358894 on cortico-limbic brain reactivity to negative emotional stimuli in major depressive disorder". European Neuropsychopharmacology. 65: 44–51. doi:10.1016/j.euroneuro.2022.10.009. hdl:2066/286079. PMID 36343427.

[3] Goettel, Markus; Fuertig, Rene; Mack, Salome Rebecca; Just, Stefan; Sharma, Vikas; Wunder, Andreas; den Boer, Johan (29 November 2023). "Effect of BI 1358894 on Cholecystokinin-Tetrapeptide (CCK-4)-Induced Anxiety, Panic Symptoms, and Stress Biomarkers: A Phase I Randomized Trial in Healthy Males". CNS Drugs. 37 (12): 1099–1109. doi:10.1007/s40263-023-01042-3. PMC 10703963. PMID 38019356.

[4] Goettel, Markus; Höfler, Josef; Fuertig, Rene; Sharma, Vikas; Göttel, Markus (May 2020). "First-In-Human Study of Oral BI 1358894 in Healthy Male Volunteers: A Phase I Study to Investigate Safety and Tolerability". Biological Psychiatry. 87 (9): S289–S290. doi:10.1016/j.biopsych.2020.02.747. S2CID 218537025.

[1]

[2]

[3]

[4]